Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
Key facts
- Who runs it
- Sanjay R Patel
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 30 Sept 2025
- Expected to end
- Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Acetazolamide
- Placebo
- Record updated
- 25 June 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients on Medication for Opioid Use Disorder (MOUD) with central sleep apnea
Who cannot take part
- Sleep-related Hypoventilation
- Other causes of Central Sleep Apnea besides Opioid Use
- Pregnancy
- Contraindications for Acetazolamide
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United States
- University of PittsburghPittsburgh, United StatesContact: Madeline GudobbaTaking people
About the trial
What the trial wants to find out
Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.
The 2 groups in the trial
- AcetazolamideTreatment being tested
All participants in this group will receive one acetazolamide 250 mg pill in the evening for 7 days.
- PlaceboPlacebo, for comparison
All participants in this group will receive one matching placebo pill in the evening for 7 days.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder
- Criteria questions
- Built from NCT06521476, who can take part
- Record updated
- 25 June 2026